Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.

Bada, Florence O; Blok, Nick; Okpokoro, Evaezi; Dutt, Saswata; Akolo, Christopher; Dakum, Patrick; Abimiku, Alash'le

Bada, Florence O; Blok, Nick; Okpokoro, Evaezi; Dutt, Saswata; Akolo, Christopher; Dakum, Patrick; Abimiku, Alash'le.

Affiliation

Bada FO; International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.
Blok N; Department of Epidemiology and Public Health, University of Maryland Graduate School, Baltimore, Maryland, United States of America.
Okpokoro E; KNCV Tuberculosis Foundation, The Hague, The Netherlands.
Dutt S; International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.
Akolo C; FHI 360, Washington, DC, United States of America.
Dakum P; FHI 360, Washington, DC, United States of America.
Abimiku A; Department of Prevention, Care and Treatment, Institute of Human Virology, Abuja, Nigeria.

PLoS One ; 15(12): e0241065, 2020.

Article in En | MEDLINE | ID: mdl-33259492

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Health Care Costs / Cost-Benefit Analysis / Tuberculosis, Multidrug-Resistant Type of study: Guideline / Health_economic_evaluation Limits: Female / Humans / Male Country/Region as subject: Africa Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2020 Document type: Article Affiliation country: Nigeria Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google